Market revenue in 2022 | USD 2,360.4 million |
Market revenue in 2030 | USD 2,777.9 million |
Growth rate | 2.1% (CAGR from 2022 to 2030) |
Largest segment | Branded |
Fastest growing segment | Generics |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Branded, Generics |
Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 69.09% in 2022. Horizon Databook has segmented the Germany gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
Germany accounted for the largest share in the European region in 2019 for gastrointestinal therapeutics market. The nation’s substantial share can be attributed to the rising prevalence of Irritable Bowel Disorder (IBD), changing lifestyle of individuals, growing number of product approvals, and strategic initiatives undertaken by various major players.
Rising prevalence of IBD in the country is expected to propel the market growth in the near future. According to a research paper published by OMICS International Journals, the prevalence of ulcerative colitis in Germany is estimated to be approximately 410 per 100, 000 individuals every year.
The German Crohn’s disease/Ulcerative Colitis Association is responsible for treatment of over 320,000 individuals with chronic IBD in the country. The Association also engages in enhancing research activities in order to improve treatment options for Crohn’s disease and ulcerative colitis.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Germany gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account